Comparison

Anti-Mouse CD279 (PD-1) [Clone 29F.1A12] — Purified - 0.5 mg

Item no. LEIN-P383-0.5mg
Manufacturer Leinco Technologies
Amount 0.5 mg
Category
Type Antibody Monoclonal
Applications WB, FC, IHC
Clone 29F.1A12
Specific against Mouse (Murine, Mus musculus)
Host Rat
NCBI 18566
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Applications
FC, IHC FF, PhenoCycler®, WB
Manufacturer - Category
Primary Monoclonal Antibodies>Immune Checkpoints|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers|Primary Monoclonal Antibodies>Tumor Markers
Manufacturer - Targets
PD-1
Country of Origin
USA
Shipping Temperature
Next Day 2 - 8°C
Storage Conditions
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Product Description
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Function
Lymphocyte clonal selection, peripheral tolerance
PubMed
PD-1
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Manufacturer - Research Area
Cancer, Immunology, Inhibitory Molecules
Manufacturer - Specificity
Clone 29F.1A12 recognizes an epitope on mouse PD-1.
RRID
AB_2831656
Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
Monoclonal Antibody, PD-1, Programmed Death-1, CD279, PD 1, RMP1-14, Mouse PD-1 Functional Grade, PD1, Programmed Death-1, CD279 antigen, CD279, hPD-1, PD1, PD1hPD-l, PDCD1, programmed cell death 1, programmed cell death protein 1, Protein PD-1, SLEB2, CD279, programmed cell death 1 protein, Programmed cell death protein 1, Protein PD-1, systemic lupus erythematosus susceptibility 2, CD279, hPD-1, hPD-l, hSLE1, Mouse PD-1, Mouse PD1, PDCD1, SLEB2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close